1. Home
  2. KALV vs PNTG Comparison

KALV vs PNTG Comparison

Compare KALV & PNTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$19.95

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo The Pennant Group Inc.

PNTG

The Pennant Group Inc.

HOLD

Current Price

$31.66

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KALV
PNTG
Founded
N/A
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Nursing Services
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
KALV
PNTG
Price
$19.95
$31.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
6
Target Price
$32.60
$36.60
AVG Volume (30 Days)
1.1M
233.9K
Earning Date
05-09-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
20.00
EPS
N/A
0.84
Revenue
$50,000,000.00
$947,705,000.00
Revenue This Year
$187.19
$24.72
Revenue Next Year
$54.93
$7.61
P/E Ratio
N/A
$36.90
Revenue Growth
495.66
36.31
52 Week Low
$9.83
$21.74
52 Week High
$21.31
$35.25

Technical Indicators

Market Signals
Indicator
KALV
PNTG
Relative Strength Index (RSI) 62.29 52.58
Support Level $14.66 $28.78
Resistance Level $21.31 $31.94
Average True Range (ATR) 1.35 1.08
MACD 0.14 -0.00
Stochastic Oscillator 75.14 84.29

Price Performance

Historical Comparison
KALV
PNTG

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About PNTG The Pennant Group Inc.

Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. It operates in two segments; home health and hospice services and senior living services. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.

Share on Social Networks: